SGIP1

Across TCGA pan-cancer cohorts, SGIP1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SGIP1 data layer compared with 20 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SGIP1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SGIP1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where SGIP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.429	0.800	<.001	31	view →
HNSC	DFS	Median	III,IV	0.713	1.000	.014	13	view →
LSCC	DFS	Tertile	II,III,IV	0.514	0.895	.008	13	view →
CCRCC	DFS	Median	All	1.000	0.372	.011	3	view →
PDAC	DFS	Quartile	III,IV	0.498	1.000	.038	3	view →
GBM	DFS	Median	All	0.818	0.616	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SGIP1–LUAD (DFS)

Open the LUAD breakdown →